INTRODUCTION
============

Since the introduction of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) in the early 1990s, it has become the standard procedure and has been widely used as a less-invasive, reliable, and safe technique for cytopathologic diagnosis of solid mass lesions adjacent to the gastrointestinal tract (GIT).[@b1-gnl-11-559]--[@b3-gnl-11-559] Although several previous studies demonstrated a favorable diagnostic sensitivity (64% to 95%) with high specificity (75% to 100%) and diagnostic accuracy (83% to 95%) in the diagnosis of pancreatic tumors,[@b4-gnl-11-559]--[@b6-gnl-11-559] some limitations with a lower diagnostic yield have been reported in the evaluation of benign pancreatic lesions, neuroendocrine tumors, lymphadenopathies, and subepithelial lesions.[@b7-gnl-11-559]--[@b9-gnl-11-559]

Theoretically, the acquisition of a core tissue, which permits both histological examination and further immunohistochemical staining, might have advantages over aspiration of cytologic specimens. Various EUS-guided techniques have been explored to retrieve tissue specimens, including a conventional FNA needle and a Tru-Cut needle, with variable success and complication rates.[@b7-gnl-11-559],[@b8-gnl-11-559],[@b10-gnl-11-559]

Recently, EUS-guided fine needle aspiration biopsy (EUS-FNB) using a new core needle was developed to improve diagnostic accuracy by obtaining histologic core specimens.[@b11-gnl-11-559],[@b12-gnl-11-559] Many previous studies have revealed the advantages of a new core biopsy needle; less needle passes, more core tissue acquisitions, and higher diagnostic yields.[@b13-gnl-11-559] However, there is no available data about the comparison of the histologic specimen itself obtained from a new core biopsy needle and a conventional needle. This study aimed to compare the histologic core in the samples obtained by EUS-FNB and EUS-FNA in patients with solid mass lesions.

MATERIALS AND METHODS
=====================

1. Patients
-----------

Eligible patients referred to Kyungpook National University Medical Center for EUS-guided tissue sampling of solid mass lesions within the wall of or adjacent to the GIT were consecutively enrolled in this study. All solid masses were previously revealed by computed tomography or magnetic resonance imaging. Patients were excluded if a mass lesion was not found at EUS, if the mass had a cystic component of over 25%, if the size of target lesion was less than 2 cm or if uncorrectable coagulopathy was present. This study was approved by the Institutional Review Board of Kyungpook National University Medical Center and registered on Clinical Research Information Service (KCT0001566). Written informed consent was obtained from all patients participating in this study.

2. Endoscopic ultrasound examinations
-------------------------------------

All procedures were performed according to the standardized protocols with left-lateral decubitus position and under moderate conscious sedation using meperidine, propofol, and/or midazolam. EUS was performed by a single experienced endosonographer (C.C.) who performs over 300 interventional cases per year. Following the identification of a target lesion using a radial scanning echoendoscope (GF-UE260; Olympus Medical Systems, Tokyo, Japan), EUS-guided tissue sampling was performed with a linear echoendoscope (GF-UCT240; Olympus Medical Systems).

3. Technique for endoscopic ultrasound-guided tissue sampling
-------------------------------------------------------------

The assignment of random numbers generated by computer were placed in sealed envelopes and opened by the nurse during the procedure if patients met the criteria for study inclusion. Patients were then randomized to undergo EUS-FNA using a 22-gauge conventional needle (EchoTip; Wilson-Cook Medical, Winston-Salem, NC, USA) or EUS-FNB using a 22-gauge core biopsy needle (EchoTip ProCore; Wilson-Cook Medical).

Once a target lesion was identified and the overlying vasculature was excluded using color Doppler flow, the needle was advanced through the instrument channel of the echoendoscope into the lesion. After puncturing the mass using the assigned needle, the stylet was slowly pulled by moving the needle to-and-fro within the lesion.[@b14-gnl-11-559] If a core specimen was not obtained using the slow pull technique, suction using a 10-mL syringe was applied at the discretion of the performing endoscopist. The acquired tissue material was expelled into a formalin containing bottle by reinserting the stylet within the needle assembly. By examining the thread-like specimen, the endosonographer determined whether a visible core tissue has been obtained. Up to three needle passes were allowed until the core tissue specimen was acquired; no on-site cytologic examination was performed. If the initial three passes failed to retrieve an adequate specimen or in cases of technical failure (defined as malfunction of the needle during EUS-guided tissue sampling), the procedure was crossed over using the other needle in the study for up to three passes until sufficient diagnostic material was obtained.

4. Histological assessment
--------------------------

The core specimens obtained from both techniques were fixed in formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for histopathological evaluation. Additional immunohistochemical staining was performed for cases in which an adequate histological specimen was acquired. For histological assessment, a cytopathologist evaluated whether the tissue is sufficient to provide histologic diagnosis and undergo additional desired immunohistochemical studies. The cytopathologist was blinded to the needle type used during the procedure.

5. Measurement of the total area and the core tissue area
---------------------------------------------------------

H&E stained slides were scanned using a digital microscopy scanner of Panoramic MIDI (3DHistech, Budapest, Hungary) with a magnifying power of ×40 and exported as a TIFF image for analyzing the total area and the histologic core area from the acquired specimen ([Figs 1](#f1-gnl-11-559){ref-type="fig"} and [2](#f2-gnl-11-559){ref-type="fig"}).

Using ImageJ software version 1.49f (National Institutes of Health, Bethesda, MD, USA), the exported TIFF images were used to measure and calculate both overall area and histologic core area. To measure total area in a scanned slide, the original scale was removed to unify the unit as pixel and the color image was converted to 8-bit gray scale. The image was adjusted to include all tissue materials by setting the minimum size as 50 and the maximum size as infinity. The total area was automatically calculated as pixels. Histologic core was defined as an architecturally correct piece of tissue sufficient for histologic evaluation. The area of the histologic core was measured using the freehand selection tool by a single cytopathologist (J.J.). The portion of histologic core was calculated dividing the histologic core area by the overall area and was then expressed as a percentage. The tutorials and examples for area measurements and particle counting were described in the web homepage of ImageJ (<https://imagej.nih.gov/ij/docs/pdfs/examples.pdf>).

6. Outcome parameters
---------------------

The primary objective in this analysis was to compare the areas of the overall specimen and histologic core acquired by both techniques. The secondary objective was to compare the median number of passes required to obtain a core specimen (visible core), the technical success rate, diagnostic accuracy, and complication rates.

We defined the diagnostic accuracy as the sum of true-positive and true-negative results divided by the total number of specimens. All patients were followed for at least 1 year. Final diagnoses were made by either one of the following methods: (1) the histological assessment from surgically resected specimen; (2) the combined assessment of the EUS-FNA and EUS-FNB samples for the clinical/imaging findings compatible with malignant or benign diseases; and (3) negative results of EUS-FNA or EUS-FNB and no evidence of malignancy on clinical/ imaging follow-up of at least 1 year.

We defined adverse events as any postprocedure event attributable to EUS-FNA or EUS-FNB. All patients were hospitalized for at least 1 day after the procedure, and were observed for immediate adverse events. To monitor delayed adverse events, patients were interviewed by a routine telephone contact 1 week and 30 days after the procedure.

7. Statistical analyses
-----------------------

Two-tailed sample size calculation was performed with a type I error (α) of 0.05 and a power of 80% for detecting a difference in the proportion of histologic core tissue between the EUS-FNA and EUS-FNB groups. Due to the lack of previous results for comparison, we referred to our own data. In the pilot trial, the average percentage of histologic core proportion from the acquired sample from EUS-FNA procedure was 10%. Under the primary study hypothesis that EUS-FNB would provide more core tissue than EUS-FNA, we further assumed that EUS-FNB allowed a histologic core portion of 20% from the samples. The calculation yielded a target sample size of 29 for each cohort.

Categorical data were expressed as frequencies and proportions and compared using chi-square test or Fisher exact test as indicated. Continuous data were summarized as means with standard deviation (SD) and compared with the two-sample t-test, or the Wilcoxon rank-sum test. All statistical analyses were compiled using SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA), with results considered significant at p-values of less than 0.05.

RESULTS
=======

1. Patient demographics and characteristics
-------------------------------------------

Between April 2013 and May 2014, a total of 58 patients were enrolled and randomized for the study. Their demographic details and lesion characteristics are presented in [Table 1](#t1-gnl-11-559){ref-type="table"}. No significant differences in patient age, sex, location and size of the tumor were detected between the EUS-FNA and EUS-FNB groups. Fewer needle passes were performed in the EUS-FNB group compared to the EUS-FNA group (1 vs 2, p\<0.001). Patient flow through the study protocol is summarized in [Fig. 3](#f3-gnl-11-559){ref-type="fig"}. No technical failure occurred in either group. Using the initial assigned needle, a visible core acquisition failed in two patients of the EUS-FNA group; each case of esophageal subepithelial lesion and pancreatic mass. Visible core tissue was successfully obtained in all cases of EUS-FNB group. Finally, 31 cases of EUS-FNB and 27 cases of EUS-FNA were included and compared for the primary and secondary objectives as per protocol analysis.

The final diagnosis at each target site is shown in [Table 2](#t2-gnl-11-559){ref-type="table"}. The final diagnosis was based on surgical pathology in 13 patients (22.4%), EUS-FNA in 18 patients (31.0%), EUS-FNB in 17 patients (29.3%), and clinical/imaging follow-up in two patients (3.4%). Among the enrolled patients, final diagnosis was inconclusive due to the inadequate tissue specimen and loss of follow-up after EUS-guided tissue sampling in each four patients of the EUS-FNA and the EUS-FNB group.

2. Comparison of total area and histologic core area of the two techniques
--------------------------------------------------------------------------

The overall area (megapixels, mean±SD) of the histologic slide prepared from specimens obtained by the EUS-FNB and the EUS-FNA were 1.26±1.09 and 1.73±1.84, respectively, with no significant difference (p=0.228) observed. When excluding the bias for needle pass, the overall area per needle pass was similar for the two techniques (0.93±0.77 and 0.76±0.69, respectively; p=0.370).

There were no statistical differences in the histologic core area of the total needle pass and per needle pass between the two techniques ([Table 3](#t3-gnl-11-559){ref-type="table"}). The proportion of histologic core tissue in terms of total area was also not significantly different between the FNB and FNA groups (11.8% vs 8.0%, p=0.376).

3. Diagnostic accuracy between EUS-FNB and EUS-FNA
--------------------------------------------------

The overall diagnostic accuracies per protocol were 80.6% and 81.5% in the EUS-FNB (n=31) and EUS-FNA (n=27) groups, respectively. No significant difference in diagnostic accuracy was noted between two techniques (p=0.935). Comparing the diagnostic accuracy by intention-to-treat analysis, there was no significant difference between EUS-FNB (23/29, 79.3%) and EUS-FNA (22/29, 75.9%) (p=1.0). When stratified according to the specimen acquisition site, the diagnostic accuracy was also not different between the two groups ([Table 4](#t4-gnl-11-559){ref-type="table"}). No adverse events were observed in all cases.

DISCUSSION
==========

EUS-FNA has been established as a safe and useful procedure for obtaining tissue samples from the wall of or adjacent to the GIT, including those from the pancreas and the retroperitoneum. However, the EUS-FNA technique has several limitations. First, the cytologic specimen alone is insufficient to verify cellular arrangement and tissue architecture.[@b15-gnl-11-559] Therefore, it has a limited value in the diagnosis of certain disease entities, including gastrointestinal stromal tumors, lymphomas, well-differentiated adenocarcinomas, or autoimmune pancreatitis.[@b8-gnl-11-559],[@b16-gnl-11-559],[@b17-gnl-11-559] Second, the success of EUS-FNA is greatly influenced by the definition used for diagnostic cytology and other methodological factors, such as availability of on-site evaluation, number of needle passes, and size of the needle.[@b18-gnl-11-559]--[@b21-gnl-11-559]

Recently, a new FNB needle with the application of reversed bevel technology has been developed to overcome these limitations of the EUS-FNA technique and to improve diagnostic accuracy by obtaining histologic core samples. The EUS-FNB needle was believed to improve diagnostic performance by providing better histological diagnostic accuracy; however, a recent randomized prospective study did not show any differences in the diagnostic yield or technical performance of the core biopsy needle compared to the conventional needle.[@b11-gnl-11-559],[@b13-gnl-11-559] In a small randomized trial including a total of 56 patients, EUS-FNB had comparable diagnostic yield to that of FNA (89.3% vs 100%, p=0.236) with a similar number of needle passes (1.61 vs 1.28, p=0.209).[@b11-gnl-11-559] Although the EUS-FNB successfully procured material for cytological assessment, it was unsatisfactory for acquiring core biopsy material for histology. The authors concluded that while EUS-FNB obtained adequate aspirates for cytology, histological sampling with the 22-gauge EUS-FNB needle was unsatisfactory.

Another prospective study also demonstrated comparable diagnostic accuracy between FNB and conventional FNA needles. They suggested similar amounts of core acquisition as a possible explanation for the comparable results between the FNB and FNA groups.[@b13-gnl-11-559] Given that there is no data available comparing the histologic specimen itself obtained from a core biopsy needle and a conventional needle, we directly compared the proportion of histologic core obtained by the two techniques. Our study showed there was no significant difference in the percentage of histologic core portion obtained and the diagnostic accuracy between the two techniques. Therefore, we confirmed that the similar diagnostic accuracy of the two methods observed in previous studies could essentially be attributed to a comparable yield of histologic core specimen.

Despite the comparable yield of the histologic core specimen, the number of needle passes was significantly lower in the FNB group, which was compatible with previous reports.[@b13-gnl-11-559],[@b22-gnl-11-559] The reverse bevel might have allowed a greater possibility of obtaining a suitable histologic core sample. The advantages of a fewer number of needle passes includes lower costs and less complications, as well as a reduction in procedure duration and need for anesthesia. In our study, needle passes were permitted up to three times until a visible core was acquired. Once a visible core was obtained, no additional needle passes were performed. Considering the fewer needle passes in the EUS-FNB group and the comparable yield of histologic cores, an equivalent number of needles passes in the two groups may have enhanced the yield of the histologic core in the EUS-FNB group. Previous investigations showing that diagnostic sensitivity improved as the number of passes increased would support our suggestion of favoring the FNB needle.[@b23-gnl-11-559]

This study has several limitations. First, this study was conducted at a single center, and the results may not reflect practices performed at other institutions. Second, an endoscopist, not an on-site pathologist, determined appropriate sample sizes containing a visible core; however, this is the current practice in majority of the facilities. Third, cytology data were not compared in this study, despite the final diagnosis depending on cytology as well as histology results. The comparable diagnostic grade of the cytology classification achieved between the two groups may support the hypothesis that a similar diagnostic accuracy between the two groups could be attributed to the similar amount of histologic core specimen obtained. Finally, various types of solid masses were included in the present study, possibly leading to heterogeneity of the study population. However, this enrollment criterion is compatible with current practice, given the widespread indications of EUS-FNA or EUS-FNB currently available, including subepithelial tumors, retroperitoneal masses, and lymph node enlargement, as well as pancreatic tumors.[@b24-gnl-11-559]

Despite these limitations, our study has several important strengths that outweigh its weaknesses. First, this is the first trial comparing the actual histologic core specimen obtained by FNB and FNA needles. Second, our study was performed with a prospective randomized design. Finally, a single experienced endoscopist performed all procedures; this minimized the possible bias and established standardization of the procedures.

In conclusion, as compared to EUS-FNA, EUS-FNB required fewer needle passes to establish a diagnosis for solid mass lesions. However, once an adequate sample containing visible core was obtained, the amount or the proportion of histologic core and the diagnostic accuracy were comparable for the two techniques.
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![Example of the measurement of overall and core portion areas. (A) Gross finding of an endoscopic ultrasound-guided fine needle aspiration specimen (×40). (B) Hematoxylin and eosin staining of a histologic slide preparation. (C) Measurement of the overall area of the acquired specimen as 599,746 pixels (×40). (D) Core tissue areas within redline measured 95,801 pixels.](gnl-11-559f1){#f1-gnl-11-559}

![Example of the measurement of overall and core portion areas. (A) Gross findings of the endoscopic ultrasound-guided fine needle biopsy specimen (×40). (B) Hematoxylin and eosin staining of the histologic slide preparation. (C) Measurement of the overall area of the acquired specimen as 936,167 pixels (×40). (D) Core tissue areas within redline measured 58,292 pixels.](gnl-11-559f2){#f2-gnl-11-559}

![Flow diagram of the study protocol.\
EUS-FNA, endoscopic ultrasound-guided fine needle aspiration; EUS-FNB, endoscopic ultrasound-guided fine needle biopsy.](gnl-11-559f3){#f3-gnl-11-559}

###### 

Baseline Characteristics between the Endoscopic Ultrasound-Guided Fine Needle Biopsy and Endoscopic Ultrasound-Guided Fine Needle Aspiration Groups

  Variable                 EUS-FNB (n=29)   EUS-FNA (n=29)   p-value
  ------------------------ ---------------- ---------------- ---------
  Sex, male:female         22:7             18:11            0.390
  Age, yr                  66 (36--81)      69 (26--85)      0.534
  Site                                                       0.927
   Pancreas                8                8                
   Lymph node              6                8                
   Subepithelial lesions                                     
    Esophagus              0                1                
    Stomach                6                3                
    Small bowel            1                1                
    Rectum                 1                1                
   Others                                                    
    Liver                  3                4                
    Retroperitoneum        2                2                
    Bile duct              1                1                
    Adrenal gland          1                0                
  Size, mm                                                   
   Longest diameter        37.5±20.6        44.3±32.3        0.348
   Shortest diameter       30.0±16.7        33.8±23.3        0.471
  Approach                                                   0.993
   Transesophageal         3                3                
   Transgastric            17               16               
   Transduodenal           8                9                
   Transrectal             1                1                
  No. of needle passes     1 (1--3)         2 (1--3)         \<0.001

Data are presented as number, median (range), or mean±SD.

EUS-FNB, endoscopic ultrasound-guided fine needle biopsy; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.

###### 

Final Diagnosis According to the Target Site in Both Groups

  Target site                                                      EUS-FNB (n=31)   EUS-FNA (n=27)
  ---------------------------------------------------------------- ---------------- ----------------
  Pancreas                                                                          
   Pancreatic ductal adenocarcinoma                                5                3
   Neuroendocrine tumor                                            \-               1
   Autoimmune pancreatitis                                         \-               1
   Chronic pancreatitis                                            1                \-
   Inflammatory pseudotumor                                        1                \-
   No final diagnosis[\*](#tfn5-gnl-11-559){ref-type="table-fn"}   2                2
  Lymph node                                                                        
   Malignancy lymphadenopathy                                      4                4
   Tuberculous lymphadenopathy                                     1                2
   No final diagnosis[\*](#tfn5-gnl-11-559){ref-type="table-fn"}   1                2
  Subepithelial lesions                                                             
   Gastrointestinal stromal tumor                                  5                4
   Gastric cancer                                                  \-               1
   Esophageal cancer                                               1                \-
   Glomus tumor                                                    1                \-
   Leiomyoma                                                       1                \-
   Malignant lymphoma                                              1                \-
  Others                                                                            
   Cholangiocarcinoma, extrahepatic                                1                1
   Cholangiocarcinoma, intrahepatic                                2                2
   Neurogenic tumor                                                1                2
   Malignant lymphoma                                              1                \-
   Hepatocellular carcinoma                                        1                \-
   Hepatic metastasis                                              \-               2
   No final diagnosis[\*](#tfn5-gnl-11-559){ref-type="table-fn"}   1                \-

Data are presented as number.

EUS-FNB, endoscopic ultrasound-guided fine needle biopsy; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.

No final diagnosis due to the inadequate specimen and the loss to follow-up after EUS-guided tissue sampling.

###### 

Comparison of the Areas of Histologic Specimens Acquired by the Endoscopic Ultrasound-Guided Fine Needle Biopsy and Endoscopic Ultrasound-Guided Fine Needle Aspiration Techniques

                                                                         EUS-FNB (n=31)   EUS-FNA (n=27)   p-value
  ---------------------------------------------------------------------- ---------------- ---------------- ---------
  Overall area, megapixels                                                                                 
   Total needle pass                                                     1.26±1.09        1.73±1.84        0.228
   Per needle pass                                                       0.93±0.77        0.76±0.69        0.370
  Core tissue area, megapixels                                                                             
   Total needle pass                                                     0.10±0.22        0.09±0.12        0.925
   Per needle pass                                                       0.06±0.11        0.04±0.06        0.595
  Efficient core portion, %[\*](#tfn8-gnl-11-559){ref-type="table-fn"}   11.8±19.5        8.0±11.1         0.376

Data are presented as mean±SD.

EUS-FNB, endoscopic ultrasound-guided fine needle biopsy; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.

Expressed as percentage of core tissue area divided by overall area.

###### 

Diagnostic Accuracy of the Endoscopic Ultrasound-Guided Fine Needle Biopsy and Endoscopic Ultrasound-Guided Fine Needle Aspiration Techniques

                          EUS-FNB (n=31)   EUS-FNA (n=27)   p-value
  ----------------------- ---------------- ---------------- ---------
  Overall                 25/31 (80.6)     22/27 (81.5)     0.935
   Pancreas               5/9 (55.6)       4/7 (57.1)       0.949
   Subepithelial lesion   9/9 (100)        5/5 (100)        0.999
   Lymph node             5/6 (83.3)       6/8 (75.0)       0.707
   Others                 6/7 (85.7)       7/7 (100)        0.299

Data are presented as number/total number (%).

EUS-FNB, endoscopic ultrasound-guided fine needle biopsy; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration.
